The effects of agomelatine on sexual function in depressed patients and healthy volunteers.

摘要

BACKGROUND: Selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor antidepressants are associated with high rates of treatment-emergent sexual dysfunction (TESD) due to stimulation of serotonin receptors. OBJECTIVE: The objective is to evaluate the effect of agomelatine on sexual function in depressed patients. METHODS: This paper reviews published and unpublished data on sexual function with agomelatine in depressed patients and healthy volunteers. RESULTS: Agomelatine, an agonist of melatonergic MT1 and MT2 receptors and antagonist of 5-HT2 receptors, is associated with similar rates of sexual dysfunction compared with placebo and lower rates compared with other antidepressants. Twice as many sexually active depressed patients (n = 193) reported a deterioration of sexual function during 12 weeks of treatment with venlafaxine compared with agomelatine (15.2 vs. 8.2, p < 0.0001); however, no differences were found with respect to arousal. Using the Arizona Sexual Experience Scale in depressed patients (n = 399), the incidence of treatment-emergent sexual dysfunction (TESD) with agomelatine (3) was significantly lower than placebo (8.6) and selective serotonin reuptake inhibitors (10.1). Among healthy male volunteers (n = 92), TESD was not increased compared with placebo in either agomelatine (25 and 50 mg/day) group over 8 weeks, and both were significantly lower than TESD with paroxetine (p < 0.0001). Moderate or severe TESD occurred in less than 5 of subjects receiving agomelatine versus 62 who received paroxetine (p < 0.001). CONCLUSION: Agomelatine demonstrates favorable sexual acceptability.